Patents Represented by Attorney, Agent or Law Firm Charles E. Cohen
  • Cyclic peptide CXCR4 antagonists
    Patent number: 7691813
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: April 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • Modulation of eIF4E expression
    Patent number: 7601700
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: October 13, 2009
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • Modulation of survivin expression
    Patent number: 7541344
    Abstract: Compounds and compositions are provided for modulating the expression of survivin. The compounds, exemplified by those acting through an RNAi antisense mechanism of action, include double-stranded and single-stranded constructs, as well as siRNAs, canonical siRNAs, blunt-ended siRNAs and single-stranded antisense RNA compounds. Methods of using these compounds for modulation of survivin expression and for treatment of diseases associated with expression of survivin are provided.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: June 2, 2009
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Bharvin Kumar Patel, Eric Swayze
  • Pyridinylmorpholine derivatives
    Patent number: 7488728
    Abstract: The invention relates to compounds of formula (I): wherein R, R1, R2 and X are defined herein, their preparation, and their use as pharmaceuticals.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: February 10, 2009
    Assignee: Eli Lilly and Company
    Inventors: Barry Peter Clark, Peter Thaddeus Gallagher
  • Humanized anti-ghrelin antibodies
    Patent number: 7479271
    Abstract: Humanized antibodies, or antigen-binding portions thereof, that preferentially bind acylated ghrelin with respect to unacylated ghrelin, are disclosed. These molecules have high affinity and a slow off rate for acylated ghrelin, and neutralize acylated ghrelin activity. These antibodies, or antigen-binding portions thereof, are useful for neutralizing acylated ghrelin activity, e.g., in a subject suffering from a disorder in which ghrelin activity is detrimental, such as obesity.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: January 20, 2009
    Assignee: Eli Lilly and Company
    Inventors: David Matthew Marquis, Alain Philippe Vasserot, Derrick Ryan Witcher
  • Modulation of eIF4E expression
    Patent number: 7425544
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: September 16, 2008
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • Inhibitor of monoamine uptake
    Patent number: 7384983
    Abstract: The present invention provides compounds and methods for the inhibition of monoamine uptake in mammals.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: June 10, 2008
    Assignee: Eli Lilly and Company
    Inventors: Edward Louis Mattiuz, John-Michael Sauer, William Joe Wheeler, David Taiwai Wong
  • 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
    Patent number: 7384941
    Abstract: Compounds of formula (I): wherein A is S or O; R is H; Ar is an optionally substituted phenyl group; X is an optionally substituted phenyl group, a C1-C4 alkyl, a C3-C6 cycloalkyl group or a CH2(C3-C6 cycloalkyl) group; R? is H or C1-C4 alkyl; and each R1 is independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof are selective inhibitors of norepinephrine reuptake.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: June 10, 2008
    Assignee: Eli Lilly and Company
    Inventors: Magnus Wilhelm Walter, Barry Peter Clark, Peter Thaddeus Gallagher, Helen Louise Haughton, Hélène Catherine Eugénie Rudyk
  • Aryl and heteroaryl morpholine derivatives
    Patent number: 7354920
    Abstract: Compounds of formula (I) wherein Rx is H; Ry is H or C1-C4 alkyl; each Rz is independently H or C1-C4 alkyl; X represents O; Y represents OH or OR; R is C1-C4 alkyl; and Ar1 and Ar2 are optionally substituted phenyl or 5- or 6-membered heteroaryl rings are selective inhibitors of the reuptake of norepinephrine.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: April 8, 2008
    Assignee: Eli Lilly and Company
    Inventors: Manuel Javier Cases-Thomas, Helen Louise Haughton, Robin George Simmonds, Hélène Catherine Eugénie Rudyk, Magnus Wilhelm Walter, Sivi Ouwerkerk-Mahadevan, John Joseph Masters, Carlos Lamas-Peteira
  • Antisense oligonucleotide modulation of STAT3 expression
    Patent number: 7307069
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: December 11, 2007
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: James G. Karras
  • Antisense modulation of survivin expression
    Patent number: 7288530
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Survivin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Survivin. Methods of using these compounds for modulation of Survivin expression and for treatment of diseases associated with expression of Survivin are provided.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: October 30, 2007
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Elizabeth J. Ackermann, Lex M. Cowsert
  • Pseudomycin production by Pseudomonas syringae
    Patent number: 6919188
    Abstract: The present invention is directed to a family of unique antimycotic lipopeptide compounds produced by Pseudomonas viridiflava. The lipopeptides are effective against both human and plant fungal pathogens, and are typically characterized by their ability to inhibit growth of Candida albicans. Representative lipopeptides of the invention have molecular weights of 1137, 1153, 1164 and 1181 daltons.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: July 19, 2005
    Assignee: Eli Lilly and Company
    Inventors: Matthew Dale Hilton, Robert Joseph Strobel, Penelope Jane Beverly Millar, Dennis Nelson Thomas, Andrew Richard Cockshott, Brian Gerald Getman, Jack Richard Eastridge, Cathleen Alice Cantwell
  • Treatment of psoriasis
    Patent number: 6683114
    Abstract: Norepinephrine reuptake inhibitors are used to treat psoriasis.
    Type: Grant
    Filed: August 7, 2002
    Date of Patent: January 27, 2004
    Assignee: Eli Lilly and Company
    Inventor: Holly Read Thomasson
  • Recombinant DNA compounds that encode ACV synthetase activity of Cephalosporium acremonium
    Patent number: 6322998
    Abstract: The present invention provides DNA compounds that encode ACV synthetase activity of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Cephalosporium, and Aspergillus.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: November 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: Cathleen A. Cantwell, Roland L. Hodges, JoAnn Hoskins, Stephen W. Queener, Paul L. Skatrud
  • Penicillin binding protein from Streptococcus pneumoniae
    Patent number: H2021
    Abstract: The invention provides isolated nucleic acid compounds encoding a novel high molecular weight PBP of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the PBP and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the PBP.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: May 7, 2002
    Assignee: Eli Lilly and Company
    Inventors: JoAnn Hoskins, Stanley Richard Jaskunas, Jr., Genshi Zhao, Pamela Kay Rockey
  • Inositolphosphoryl ceramide (IPC) synthase genes from fungi
    Patent number: H2022
    Abstract: The invention provides isolated nucleic acid compounds encoding IPC synthase or subunit thereof from fungal cells. Also provided are vectors and transformed heterologous host cells for expressing IPC synthase and a method for identifying compounds that inhibit a fungal IPC synthase.
    Type: Grant
    Filed: March 10, 1998
    Date of Patent: May 7, 2002
    Assignee: Eli Lilly and Company
    Inventors: Steven Alan Heidler, Jeffrey Alan Radding
  • Streptococcus pneumoniae sequence GrpE
    Patent number: H2023
    Abstract: The invention provides isolated nucleic acid compounds encoding GrpE of Streptococcus pneumoniae. Also provided are vectors and transformed host cells for expressing the encoded protein, and a method for identifying compounds that bind and/or inhibit said protein.
    Type: Grant
    Filed: December 8, 1997
    Date of Patent: May 7, 2002
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, Stanley Richard Jaskunas, Jr., Pamela Kay Rockey, Patti Jean Treadway
  • Streptococcus pneumoniae gene sequence for DNA ligase
    Patent number: H2070
    Abstract: The invention provides isolated nucleic acid compounds encoding a DNA ligase of Streptococcus pneumoniae. Also provided are vectors and transformed host cells for expressing the encoded protein, and a method for identifying compounds that bind and/or inhibit said protein.
    Type: Grant
    Filed: December 8, 1997
    Date of Patent: July 1, 2003
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, Stanley Richard Jaskunas, Jr., Timothy Ivan Meier, Pamela Kay Rockey, Genshi Zhao
  • Streptococcus pneumoniae gene HI0454
    Patent number: H2071
    Abstract: The invention provides isolated nucleic acid compounds encoding the 454 gene of Streptococcus pneumoniae. Also provided are vectors and transformed host cells for expressing the encoded protein, and a method for identifying compounds that bind and/or inhibit said protein.
    Type: Grant
    Filed: December 8, 1997
    Date of Patent: July 1, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert Brown Peery, Paul Luther Skatrud, Michele Louise Young Bellido, Patti Jean Treadway
  • Penicillin binding protein from Streptococcus pneumoniae
    Patent number: H2085
    Abstract: The invention provides isolated nucleic acid compounds encoding a novel high molecular weight PBP of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the PBP and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the PBP.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: October 7, 2003
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, S. Richard Jaskunas, Jr., Genshi Zhao, Pamela K. Rockey, Paul R. Rosteck, Jr., Franklin H. Norris